Drug Profile
Research programme: non-influenza vaccine - Medicago/undisclosed company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medicago; Unknown
- Developer Medicago
- Class Virus-like particle vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Canada
- 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
- 06 Apr 2011 Preclinical trials in Undefined indication in Canada (unspecified route)